Astellas Signs Up for Access Accelerated
January 19, 2017
Astellas Pharma is the latest company to announce its participation in Access Accelerated, a global, multi-stakeholder initiative to advance access to non-communicable disease (NCD) prevention, diagnostics and treatment in low-income and lower-middle income countries.
Access Accelerated comprises 22 leading pharmaceutical companies, who, in collaboration with the World Bank Group and the Union for International Cancer Control (UICC), will work towards the United Nations Sustainable Development Goal target to reduce premature deaths from NCDs by one-third by 2030.
The contributing companies include Almirall, Astellas, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, EFPIA, GlaxoSmithKline, The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Johnson & Johnson, JPMA, Menarini, Merck, MSD, Novartis, Pfizer, PhRMA, Roche, Sanofi, Shionogi, Sumitomo Dainippon, Takeda and UCB.
IFPMA will act as the Secretariat for Access Accelerated.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
